本帖最后由 成长的烦恼 于 2012-6-27 20:19 编辑
0 d0 G2 n, b" q$ W( {
6 c1 D* S `0 u% O' O+ b) S: Uclinicaltrials上的三期临床链接) d9 {% g( p: @) M) K8 Y& g7 h
9 S+ a4 q1 z6 K9 @( T* E7 {
http://clinicaltrials.gov/ct2/sh ... mp;show_locs=Y#locn
+ g; b: N) C# s; d8 M! x, N
/ G/ ^1 f/ E) u, c0 ?6 [7 ~7 e/ G' ]中国参加临床实验的城市
5 s M3 J& M8 p+ k+ s; ]0 N6 Y5 C# D
China, Guangdong
+ g/ [0 N7 ?* t7 I % [ e6 M1 \- B- o& K0 p4 L( f2 e
Guangzhou, Guangdong, China, 510515
4 A/ C& b$ w \. u9 P
: m. b+ x' R$ G, gGuangzhou, Guangdong, China, 510060 ( h4 I+ w3 I+ K3 ^
China, Jiangsu
0 c p/ j6 S* Y) g 7 m, K2 Z. \2 t
Nanjing, Jiangsu, China, 210009
9 |0 m9 p4 [- }3 X* s5 K $ ?! X1 U, y( N- ^+ s5 u; p, P
Nanjing, Jiangsu, China, 210002 8 E7 K2 \/ B; Y Q
China, Shandong " C, B! F. O* L! r. C6 m6 n
0 e1 e3 z! a F' H3 v2 X
Qingdao, Shandong, China, 266003 $ g$ }- Z4 g- K i" D
China
" s8 E% g m. z$ r* `/ M 4 q) Z3 |2 F+ ^; B; p, R
Beijing, China, 100021 9 x2 h9 S( I3 t! e, y
; A7 u% H1 j4 GBeijing, China, 100071
% [, `6 v6 \) y2 b" N; | " Z' ]' r" i: |' t& F
Changchun, China, 130021
# e; [' |; k8 J2 D5 M# g
5 ^' d, ]- z9 d/ Z; }Chongqing, China, 400042 , o7 T" S+ Q K' a' N
& t# N6 Z# _! {. \9 s& y U
Chongqing, China, 400038
0 z2 X& h9 N: C
$ m) }5 M. j/ w. u/ DFuzhou, China, 350014
0 y9 r5 G1 U: @) S- U4 q! K* d, K& J' B
3 m8 |& l" g. }9 `7 FFuzhou, China, 350025
( G3 X# Q2 s# A # Z6 s. @0 X- U! d# R9 ]0 ^9 H5 x
Ha'erbin, China, 150040 - X) E4 H) ^- N6 [1 R
# Z# H1 a2 |: J/ z7 m# t h Y
Hanghzou, China, 310009 ; t7 M1 u0 z0 {3 W! h. S; T0 t
" t- h6 C6 d0 X; \Shanghai, China, 200001
$ E. G; [' s( E: r% I- X ' N% w) H9 ~' N2 N6 {* A6 d
Shanghai, China, 200030
, t2 u; e1 u4 F7 Y7 C4 @8 I/ I ( T& r# m; \$ B% N& u
Tianjin, China 4 {0 l, z1 g+ L% e
3 \4 e6 i. m5 W2 z2 {. p
该实验已停止招募,重新开的临床请见临床专用贴。 |